Effects of supplementation with selenium, as selenized yeast, in a healthy male population from new Zealand

Nutrition and Cancer

Volumn 65, Issue 3, 2013, Pages 355-366

  Karunasinghe, Nishi ^a   Han, Dug Yeo ^b   Zhu, Shuotun ^a   Duan, He ^a   Ko, Yi Ju ^a   Yu, Jie Fu ^c   Triggs, Christopher M ^c   Ferguson, Lynnette R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; PEROXIDE; SELENIUM; SELENOMETHIONINE; THIOREDOXIN REDUCTASE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DNA DAMAGE; ENZYME ACTIVITY; ERYTHROCYTE; GASTROINTESTINAL REFLUX; HUMAN; HUMAN EXPERIMENT; INDIGESTION; MALE; NEW ZEALAND; NORMAL HUMAN; TRACE METAL BLOOD LEVEL; YEAST;

ADULT; AGED; AGED, 80 AND OVER; DIETARY SUPPLEMENTS; DNA; DNA DAMAGE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PEROXIDES; SELENIUM; TELOMERASE; YEASTS;

EID: 84876107457     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.760743     Document Type: Article

References (84)

1. University of Otago and Ministry of Health. 2011. A Focus on Nutrition: Key Findings of the 2008/09 New Zealand Adult Nutrition Survey, Wellington, New Zealand: Ministry of Health.
2. Combs, G F Jr. 2001. Selenium in global food systems. Br J Nutr, 85: 517-547.
3. Sheck, L, Davies, J, and, Wilson, G. 2010. Selenium and ocular health in New Zealand. N Z Med J, 123: 85-94.
4. Ferguson, L R, Karunasinghe, N, Zhu, S, and, Wang, A H. 2012. Selenium and its role in the maintenance of genomic stability. Mutat Res, 733: 100-110.
5. Davis, C D, and, Irons, R. 2005. Are selenoproteins important for the cancer protective effects of selenium?. Current Nutrition & Food Science, 1: 201-214.
6. Blasiak, J, Kadlubek, M, Kowalik, J, Romanowicz-Makowska, H, and, Pertynski, T. 2002. Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate. Teratog Carcinog Mutagen, 22: 73-82.
7. Yu, R A, Chen, H J, He, L F, Chen, B, and, Chen, X M. 2009. Telomerase activity and telomerase reverse transcriptase expression induced by selenium in rat hepatocytes. Biomed Environ Sci, 22: 311-317.
8. Schoenmakers, E, Agostini, M, Mitchell, C, Schoenmakers, N, Papp, L. 2010. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest, 120: 4220-4235.
9. Akbaraly, N T, Arnaud, J, Hininger-Favier, I, Gourlet, V, Roussel, A M. 2005. Selenium and mortality in the elderly: results from the EVA study. Clin Chem, 51: 2117-2123.
10. Hu, H, Jiang, C, Schuster, T, Li, G-X, Daniel, P T. 2006. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther, 5: 1873-1882.
11. Xiang, N, Zhao, R, and, Zhong, W. 2009. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemother Pharmacol, 63: 351-362.
12. Yamaguchi, K, Uzzo, R G, Pimkina, J, Makhov, P, Golovine, K. 2005. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene, 24: 5868-5877.
13. Arsova-Sarafinovska, Z, Matevska, N, Eken, A, Petrovski, D, Banev, S. 2009. Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol, 41: 63-70.
14. Beevi, S S, Rasheed, M H, and, Geetha, A. 2007. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin Chim Acta, 375: 119-123.
15. Reszka, E, Gromadzinska, J, Jablonska, E, Wasowicz, W, Jablonowski, Z. 2009. Level of selenoprotein transcripts in peripheral leukocytes of patients with bladder cancer and healthy individuals. Clin Chem Lab Med, 47: 1125-1132.
16. Rohr-Udilova, N, Sieghart, W, Eferl, R, Stoiber, D, Bjorkhem-Bergman, L. 2012. Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology, 55: 1112-1121.
17. Sen, S, Kawahara, B, and, Chaudhuri, G. 2012. Maintenance of higher H(2)O(2) levels, and its mechanism of action to induce growth in breast cancer cells: Important roles of bioactive catalase and PP2A. Free Radic Biol Med, Jun 27. [Epub ahead of print]
18. Arner, E S. 2009. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta, 1790: 495-526.
19. Berggren, M, Gallegos, A, Gasdaska, J R, Gasdaska, P Y, Warneke, J. 1996. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res, 16: 3459-3466.
20. Lincoln, D T, Ali Emadi, E M, Tonissen, K F, and, Clarke, F M. 2003. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res, 23: 2425-2433.
21. Clark, L C, Combs, G F Jr., Turnbull, B W, Slate, E H, Chalker, D K. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276: 1957-1963.
22. Kardinaal, A F, Kok, F J, Kohlmeier, L, Martin-Moreno, J M, Ringstad, J. 1997. Association between toenail selenium and risk of acute myocardial infarction in European men. The EURAMIC Study. European Antioxidant Myocardial Infarction and Breast Cancer. Am J Epidemiol, 145: 373-379.
23. Salonen, J T, Alfthan, G, Huttunen, J K, Pikkarainen, J, and, Puska, P. 1982. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet, 2: 175-179.
24. Virtamo, J, Valkeila, E, Alfthan, G, Punsar, S, Huttunen, J K. 1985. Serum selenium and the risk of coronary heart disease and stroke. Am J Epidemiol, 122: 276-282.
25. Lippman, S M, Klein, E A, Goodman, P J, Lucia, M S, Thompson, I M. 2009. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301: 39-51.
26. El-Bayoumy, K. 2009. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer, 61: 285-286.
27. Karunasinghe, N, Han, D Y, Zhu, S, Yu, J, Lange, K. 2012. Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr, 7: 179-190.
28. Marshall, J R, Ip, C, Romano, K, Fetterly, G, Fakih, M. 2011. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila), 4: 1938-1944.
29. Rayman, M P. 2009. Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta, 1790: 1533-1540.
30. Rayman, M P, Combs, G F Jr., and, Waters, D J. 2009. Selenium and vitamin E supplementation for cancer prevention. JAMA, 301: 1876-1882.
31. Schrauzer, G N. 2009. RE: Lessons from the selenium and vitamin E cancer prevention trial (SELECT). Crit Rev Biotechnol, 29: 81
32. Galardi, F, Oakman, C, Truglia, M C, Cappadona, S, Biggeri, A. 2012. Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast, 21: 336-342.
33. Hofmann, T, Kuhnert, A, Schubert, A, Gill, C, Rowland, I R. 2009. Modulation of detoxification enzymes by watercress: in vitro and in vivo investigations in human peripheral blood cells. Eur J Nutr, 48: 483-491.
34. Najafzadeh, M, Baumgartner, A, Gopalan, R, Davies, J B, Wright, A. 2012. In vitro sensitivities to UVA of lymphocytes from patients with colon and melanoma cancers and precancerous states in the micronucleus and the Comet assays. Mutagenesis, 27: 351-357.
35. Karunasinghe, N, Ferguson, L R, Tuckey, J, and, Masters, J. 2006. Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. J Nutr, 136: 2232-2235.
36. Wendel, A. 1981. Glutathione peroxidase. Methods Enzymol, 77: 325-333.
37. Smith, A D, and, Levander, O A. 2002. High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol, 347: 113-121.
38. Ferguson, L R, Han, D Y, Fraser, A G, Huebner, C, Lam, W J. 2010. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res, 690: 108-115.
39. Karunasinghe, N, Ryan, J, Tuckey, J, Masters, J, Jamieson, M. 2004. DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev, 13: 391-397.
40. Collins, A R, and, Horvathova, E. 2001. Oxidative DNA damage, antioxidants and DNA repair: applications of the comet assay. Biochem Soc Trans, 29: 337-341.
41. Collins, A R, Oscoz, A A, Brunborg, G, Gaivao, I, Giovannelli, L. 2008. The comet assay: topical issues. Mutagenesis, 23: 143-151.
42. Rongpu, Y, Jiachen, H, Gongkan, F, and, Zhengen, M. 1986. Fluorometric determination of micro-amounts of selenium in human blood, using 2,3-diaminonaphthalene. Med Lab Sci, 43: 331-334.
43. Watkinson, J H. 1979. Semi-automated fluorimetric determination of nanogram quantities of selenium in biological materials. Anal Chim Acta, 105: 319-325.
44. Watkinson, J H, and, Brown, M W. 1979. New phase separating device and other improvements in the semi-automated fluorimetric determination of selenium. Anal Chim Acta, 105: 451-454.
45. R Development Core Team. 2011. A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing.
46. Clark, L C, Dalkin, B, Krongrad, A, Combs, G F Jr., Turnbull, B W. 1998. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol, 81: 730-734.
47. Margaritis, I, Rousseau, A S, Hininger, I, Palazzetti, S, Arnaud, J. 2005. Increase in selenium requirements with physical activity loads in well-trained athletes is not linear. Biofactors, 23: 45-55.
48. Lynnette, R, Ferguson, N K, Zhu, S, Han, D Y., Masters, J G. 2012. Understanding heterogeneity in supplementation effects of selenium in men: a study of stratification variables and human genetics in a prospective sample from New Zealand. Current Pharmacogenomics and Personalized Medicine, 10: 204-216.
49. Westguard, Q C. 2011. Biological Variation Database specifications. http://www.westgard.com/biodatabase1.htm
50. Rayman, M P. 2004. The use of high-selenium yeast to raise selenium status: how does it measure up?. Br J Nutr, 92: 557-573.
51. European Commission Joint Research Centre. 2011. EURL Evaluation Report on the Analytical Methods Submitted in Connection with the Application for Authorisation of a Feed Additive According to Regulation (EC) No 1831/2003, Institute of Reference Materials and Measurements, European Union Reference Laboratory for Feed Additives. Geel, Belgium
52. Duffield, A J, Thomson, C D, Hill, K E, and, Williams, S. 1999. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr, 70: 896-903.
53. Thomson, C D. 2004. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr, 58: 391-402.
54. Thomson, C D, Robinson, M F, Butler, J A, and, Whanger, P D. 1993. Long-term supplementation with selenate and selenomethionine: Selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. Br J Nutr, 69: 577-588.
55. Neve, J. 1995. Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. J Trace Elem Med Biol, 9: 65-73.
56. Alfthan, G, Aro, A, Arvilommi, H, and, Huttunen, J K. 1991. Selenium metabolism and platelet glutathione peroxidase activity in healthy Finnish men: Effects of selenium yeast, selenite, and selenate. Am J Clin Nutr, 53: 120-125.
57. McCann, J C, and, Ames, B N. 2011. Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging. FASEB J, 25: 1793-1814.
58. Whanger, P D, Beilstein, M A, Thomson, C D, Robinson, M F, and, Howe, M. 1988. Blood selenium and glutathione peroxidase activity of populations in New Zealand, Oregon, and South Dakota. FASEB J, 2: 2996-3002.
59. Arner, E S, and, Holmgren, A. 2000. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem, 267: 6102-6109.
60. Holmgren, A. 1989. Thioredoxin and glutaredoxin systems. J Biol Chem, 264: 13963-13966.
61. Gilbert, H F. 1990. Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Relat Areas Mol Biol, 63: 69-172.
62. Altschmied, J, and, Haendeler, J. 2009. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid Redox Signal, 11: 1733-1740.
63. Nordberg, J, and, Arner, E S. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med, 31: 1287-1312.
64. Reeves, M A, and, Hoffmann, P R. 2009. The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci, 66: 2457-2478.
65. Xia, L, Nordman, T, Olsson, J M, Damdimopoulos, A, Bjorkhem-Bergman, L. 2003. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J Biol Chem, 278: 2141-2146.
66. Zhao, X Q, Zhao, J J, Li, X Y, Zhang, Y, and, Jiao, X Y. 2010. The change of thioredoxin system in myocardial tissue of type 2 diabetic rats undergoing myocardial injury. Sheng Li Xue Bao, 62: 261-268.
67. Zachara, B A, Gromadzinska, J, Palus, J, Zbrog, Z, Swiech, R. 2011. The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: a pilot study. Biol Trace Elem Res, 142: 274-283.
68. Schrauzer, G N. 2000. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr, 130: 1653-1656.
69. Seitomer, E, Balar, B, He, D, Copeland, P R, and, Kinzy, T G. 2008. Analysis of Saccharomyces cerevisiae null allele strains identifies a larger role for DNA damage versus oxidative stress pathways in growth inhibition by selenium. Mol Nutr Food Res, 52: 1305-1315.
70. Zhang, S, Rocourt, C, and, Cheng, W H. 2010. Selenoproteins and the aging brain. Mech Ageing Dev, 131: 253-260.
71. Rao, Y, McCooeye, M, and, Mester, Z. 2012. Mapping of sulfur metabolic pathway by LC Orbitrap mass spectrometry. Anal Chim Acta, 721: 129-136.
72. Mapelli, V, Hillestrom, P R, Kapolna, E, Larsen, E H, and, Olsson, L. 2011. Metabolic and bioprocess engineering for production of selenized yeast with increased content of seleno-methylselenocysteine. Metab Eng, 13: 282-293.
73. Wallenberg, M, Olm, E, Hebert, C, Bjornstedt, M, and, Fernandes, A P. 2010. Selenium compounds are substrates for glutaredoxins: A novel pathway for selenium metabolism and a potential mechanism for selenium-mediated cytotoxicity. Biochem J, 429: 85-93.
74. Caple, F, Williams, E A, Spiers, A, Tyson, J, Burtle, B. 2010. Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. Br J Nutr, 103: 1585-1593.
75. Rayman, M P. 2012. Selenium and human health. Lancet, 379 (9822): 1256-1268.
76. McSheehy, S, Pannier, F, Szpunar, J, Potin-Gautier, M, and, Lobinski, R. 2002. Speciation of seleno compounds in yeast aqueous extracts by three-dimensional liquid chromatography with inductively coupled plasma mass spectrometric and electrospray mass spectrometric detection. Analyst, 127: 223-229.
77. Amoako, P O, Uden, P C, and, Tyson, J F. 2009. Speciation of selenium dietary supplements; formation of S-(methylseleno)cysteine and other selenium compounds. Anal Chim Acta, 652: 315-323.
78. Block, E, Glass, R S, Jacobsen, N E, Johnson, S, Kahakachchi, C. 2004. Identification and synthesis of a novel selenium-sulfur amino acid found in selenized yeast: Rapid indirect detection NMR methods for characterizing low-level organoselenium compounds in complex matrices. J Agric Food Chem, 52: 3761-3771.
79. Chen, B, He, M, Mao, X, Cui, R, Pang, D. 2011. Ionic liquids improved reversed-phase HPLC on-line coupled with ICP-MS for selenium speciation. Talanta, 83: 724-731.
80. Ip, C, Birringer, M, Block, E, Kotrebai, M, Tyson, J F. 2000. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem, 48: 2062-2070.
81. Rao, Y, McCooeye, M, Windust, A, Bramanti, E, DUlivo, A. 2010. Mapping of selenium metabolic pathway in yeast by liquid chromatography-Orbitrap mass spectrometry. Anal Chem, 82: 8121-8130.
82. Hurst, R, Armah, C N, Dainty, J R, Hart, D J, Teucher, B. 2010. Establishing optimal selenium status: Results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr, 91: 923-931.
83. Xia, Y, Hill, K E, Li, P, Xu, J, Zhou, D. 2010. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: A placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr, 92: 525-531.
84. Burk, R F, Hill, K E, and, Motley, A K. 2001. Plasma selenium in specific and non-specific forms. Biofactors, 14: 107-114.